Abstracts tagged "Clinical research"

Abstract Number: 1209 • 2016 ACR/ARHP Annual Meeting
Sporadic Hemophagocytic Lymphohistiocytosis (sHLH): A Polygenic Disease? a Report of French National, Prospective, Cohort of 205 Patients
Coralie Bloch-Queyrat^1,2, Jean Philippe Jais³, Marine Gil⁴, Brigitte Bader-Meunier⁵, Olivier Hermine^6,7 and Genevieve de Saint-Basile⁴, ¹Clinical Research Unit, University Hospital Paris Seine Saint Denis, AP-HP, Bobigny, France, ²Laboratory of cellular and molecular mechanisms of hematological disorders and therapeutic implications INSERM U 1163 / CNRS ERL 8254 Institut IMAGINE, Paris, paris, France, ³Biostatstical Departement, Department of biostatistics Necker Enfants Malades Hospital, AP-HP, Paris, France, ⁴Normal and pathological homeostasis of the immune system laboratory Institut IMAGINE Paris, Paris, France, ⁵Pediatric Rheumatology & Immunology, Pediatric Rheumatology & Immunology, Necker hospital, Imagine Institution, Paris, France, ⁶Department of Hematology, Hôpital Necker, Paris, France, ⁷Laboratory of cellular and molecular mechanisms of hematological disorders and therapeutic implications INSERM U 1163 / CNRS ERL 8254 Labex on Red cell and iron metabolism Institut IMAGINE, Paris, France
Background/Purpose: The role of genetic factors in the occurrence and/or severity of sHLH is not yet known. Therefore, from 2010 to 2016, we performed a…
Abstract Number: 1316 • 2016 ACR/ARHP Annual Meeting
Clinical Features and Outcomes of Prosthetic Joint Septic Arthritis: The Gender Effect
Mary Louise Fowler¹, Sarah B. Lieber², Andy Moore³, Robert Shmerling⁴ and Ziv Paz², ¹Boston University School of Medicine, Boston, MA, ²Beth Israel Deaconess Medical Center, Boston, MA, ³Division of Rheumatology, Cambridge Health Alliance, Harvard Medical School, Boston, MA, ⁴Rheumatology, Beth Israel Deaconess Medical Center, Boston, MA
Background/Purpose: In developed countries, certain health outcomes are worse among men. For example, in the US, life expectancy for men is 5 years shorter than…
Abstract Number: 1321 • 2016 ACR/ARHP Annual Meeting
Distinguishing Features of Polymicrobial Septic Arthritis
Sarah B. Lieber¹, Andy Moore², Robert Shmerling³, Mary Louise Fowler⁴ and Ziv Paz¹, ¹Beth Israel Deaconess Medical Center, Boston, MA, ²Division of Rheumatology, Cambridge Health Alliance, Harvard Medical School, Boston, MA, ³Rheumatology, Beth Israel Deaconess Medical Center, Boston, MA, ⁴Boston University School of Medicine, Boston, MA
Background/Purpose: Little is known about patients with polymicrobial septic arthritis (SA) and how they may differ from those with SA due to a single organism.…
Abstract Number: 1362 • 2016 ACR/ARHP Annual Meeting
Associations Between 25-Hydroxyvitamin D, Parathyroid Hormone, and Cathelicidin Concentrations with Inflammation and Cardiovascular Risk in Subjects with Pediatric Systemic Lupus Erythematosus
Varsha Gupta¹, Vin Tangpricha², Eric Yow³, Grace McComsey⁴, Laura E. Schanberg⁵, Angela B. Robinson⁶ and APPLE Investigators Group, ¹Case Western Reserve University School of Medicine, Cleveland, OH, ²Medicine, Emory University School of Medicine, Atlanta, GA, ³Biostatistics, Duke Clinical Research Institute, Durham, NC, ⁴Pediatric Infectious Diseases, Rheumatology, and Geographic Medicine, Rainbow Babies and Children's Hospital / Case Medical Center, Cleveland, OH, ⁵Department of Pediatrics, Duke University Medical Center, Durham, NC, ⁶Pediatric Rheumatology, Rainbow Babies and Childrens Hospital, Cleveland, OH
Background/Purpose: Previous studies have shown associations between reduced serum 25-hydroxyvitamin D (25OHD) levels, inflammation, and disease activity in pediatric systemic lupus erythematosus (pSLE). The goal…
Abstract Number: 1369 • 2016 ACR/ARHP Annual Meeting
Features Distinguishing Clinically Hypo- and Amyopathic Juvenile Dermatomyositis (CAJDM) from Juvenile Dermatomyositis (JDM)
Gulnara Mamyrova¹, Takayuki Kishi², Nastaran Bayat², Ira N. Targoff³, Lan Wu², Olcay Y. Jones^1,4, Rodolfo Curiel¹, Frederick W. Miller² and Lisa G. Rider^1,2, ¹Rheumatology, George Washington University, Washington, DC, ²Environmental Autoimmunity Group, National Institute of Environmental Health Sciences, NIH, Bethesda, MD, ³University of Oklahoma, Oklahoma City, OK, ⁴Pediatrics, Walter Reed National Military Medical Center, Bethesda, MD
Background/Purpose: Clinically Amyopathic Juvenile Dermatomyositis (CAJDM) is a distinct clinical phenotype of JDM in which patients (pts) often have characteristic JDM rashes with little…
Abstract Number: 2520 • 2016 ACR/ARHP Annual Meeting
Multi-Biomarker Disease Activity (MBDA) Score and Prediction of Radiographic Progression in a Randomized Study of Patients with Early RA Treated with Methotrexate Alone or with Adalimumab
Cecilie Heegaard Brahe¹, Mikkel Østergaard², Julia Sidenius Johansen³, Nadine A. Defranoux⁴, Ching Chang Hwang⁵, Xingbin Wang⁴, Rebecca J. Bolce⁴, Eric H. Sasso⁴, Kim Hørslev-Petersen⁶, Kristian Stengaard-Pedersen⁷, Lykke Midtbøll Ørnbjerg⁸, Peter Junker⁹, Torkell Ellingsen¹⁰, Palle Ahlquist¹¹, Hanne Lindegaard¹², Asta Linauskas¹³, Annette Schlemmer¹⁴, Mette Yde Dam¹⁵, Ib Tønder Hansen¹⁶, Tine Lottenburger¹¹, Christian G. Ammitzbøll¹⁷, Anette Jørgensen¹⁷, Sophine B. Krintel⁸, Johnny Lillelund Raun¹⁸ and Merete Lund Hetland^3,19, ¹Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Denmark, Glostrup, Denmark, ²Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Denmark, Copenhagen, Denmark, ³Danish Rheumatologic Biobank and DANBIO registry, Rigshospitalet, Glostrup, Gentofte and Herlev University Hospital, Copenhagen, Denmark, ⁴Crescendo Bioscience Inc., South San Francisco, CA, ⁵Biostatistics, Crescendo Bioscience Inc., South San Francisco, CA, ⁶King Christian X Hospital for Rheumatic Diseases, Graasten, Denmark, ⁷Rigshospitalet (Glostrup and Blegdamsvej), Århus University Hospital, Odense University Hospital, Herlev/Gentofte Hospital, Slagelse Sygehus, Chr X hospital (University of South Denmark) and Zitelab Aps, DANBIO Registry and Departments of Rheumatology, Copenhagen, Denmark, ⁸Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Copenhagen, Denmark, ⁹Department of Rheumatology C, Odense University Hospital, Odense, Denmark, ¹⁰Department of Rheumatology, Odense University Hospital, Odense, DK, Odense, Denmark, ¹¹Department of Medicine, Vejle Regional Hospital, Vejle, Denmark, ¹²The DANBIO registry and the Danish Departments of Rheumatology, Odense, Denmark, ¹³The DANBIO registry and the Danish Departments of Rheumatology, Copenhagen, Denmark, ¹⁴9Department of Rheumatology, Aalborg University Hospital, Aalborg, Denmark, ¹⁵Diagnostic Centre, Silkeborg Regional Hospital, Silkeborg, Denmark, ¹⁶Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark, ¹⁷Department of Rheumatology, Institute of Clinical Medicine, Aarhus University Hospital, Aarhus, Denmark, ¹⁸King Christian X Hospital for Rheumatic Diseases, South Jutland Hospital, Graasten, Denmark, ¹⁹Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Denmark,, Copenhagen, Denmark
Background/Purpose: The multi-biomarker disease activity (MBDA) score, which combines 12 serum biomarkers to measure RA disease activity on a scale of 1−100, has been found…
Abstract Number: 3136 • 2016 ACR/ARHP Annual Meeting
Impact of Novel Smartphone Application on Pain and Mobility in Osteoarthritis Patients Treated with Hylan G-F 20
Nebojsa Skrepnik¹, Andrew Spitzer², Roy Altman³, John A. Hoekstra⁴, John Stewart⁵ and Richard Toselli⁶, ¹Tucson Orthopaedic Institute, Tucson, AZ, ²Cedars-Sinai Orthopedic Center, Los Angeles, CA, ³UCLA Medical Center, Los Angeles, CA, ⁴National Clinical Research–Richmond, Richmond, VA, ⁵Sanofi, Laval, QC, Canada, ⁶Sanofi, Cambridge, MA
Background/Purpose: Methods: In this study, both groups were treated with hylan G-F 20 and showed significantly increased mobility and reduced pain, however, patients using the…
Abstract Number: 242 • 2016 ACR/ARHP Annual Meeting
Clinical and Laboratory Features of IgG4-Related Retroperitoneal Fibrosis/Periarteritis in Japan: Retrospective Multicenter Study of 99 Cases
Ichiro Mizushima¹, Satomi Kasashima², Motohisa Yamamoto³, Takako Saeki⁴, Kazunori Yamada⁵, Dai Inoue⁶, Fuminori Kasashima⁷, Yasushi Matsumoto⁷, Eisuke Amiya⁸, Kenji Notohara⁹, Yasuharu Sato¹⁰, Yoh Zen¹¹, Shigeyuki Kawa¹², Mitsuhiro Kawano¹ and Nobukazu Ishizaka¹³, ¹Division of Rheumatology, Kanazawa University Hospital, Kanazawa, Japan, ²Department of Clinical Laboratory and Pathology, National Hospital Organization, Kanazawa Medical Center, Kanazawa, Japan, ³First Department of Internal Medicine, Sapporo Medical University School of Medicine, Sapporo, Japan, ⁴Department of Internal Medicine, Nagaoka Red Cross Hospital, Nagaoka, Japan, ⁵Department of Advanced Research in Community Medicine, Kanazawa University Graduate School of Medical Sciences, Kanazawa, Japan, ⁶Department of Radiology, Kanazawa University Graduate School of Medical Science, Kanazawa, Japan, ⁷Department of Cardiovascular Surgery, National Hospital Organization, Kanazawa Medical Center, Kanazawa, Japan, ⁸Department of Cardiovascular Medicine, University of Tokyo Graduate School of Medicine, Tokyo, Japan, ⁹Department of Pathology, Kurashiki Central Hospital, Kurashiki, Japan, ¹⁰Department of Pathology, Okayama University Graduate School of Medicine, Okayama, Japan, ¹¹Department of Diagnostic Pathology, Kobe University Graduate School of Medicine, Kobe, Japan, ¹²Center for Health, Safety and Environmental Management, Shinshu University, Matsumoto, Japan, ¹³Department of Cardiology, Osaka Medical College, Osaka, Japan
<span">Background/Purpose: IgG4-related disease (IgG4-RD) is a recently recognized systemic inflammatory disorder that can affect many organs. It frequently causes retroperitoneal/periarterial lesions, which are referred to…
Abstract Number: 311 • 2016 ACR/ARHP Annual Meeting
Comparative Effectiveness of Ayurveda and Conventional Care in Knee Osteoarthritis – a Randomized Controlled Trial
Christian Kessler^1,2, Kartar Dhiman³, Abhimanyu Kumar⁴, Thomas Ostermann⁵, Shivenarain Gupta^6,7, Antonio Morandi⁸, Martin Mittwede^7,9, Elmar Stapelfeldt², Michaela Spoo², Katja Icke¹, Andreas Michalsen^1,2 and Claudia Witt^1,10, ¹Institute for Social Medicine, Epidemiology and Health Economics, Charité University Medical Center, Berlin, Germany, ²Department for Complementary Medicine, Immanuel Hospital Berlin, Berlin, Germany, ³Central Council for Research in Ayurvedic Sciences (CCRAS), New Delhi, India, New Delhi, India, ⁴All India Institute of Ayurveda, New Delhi, India, ⁵Department of Psychology and Psychotherapy, University of Witten Herdeckey, Witten, Germany, ⁶Department of Kaya Cikitsa, J.S. Ayurveda College & P.D. Patel Ayurveda Hospital, Nadiad, India, ⁷European Academy of Ayurveda, Birstein, Germany, ⁸Ayurvedic Point, School of Ayurvedic Medicine, Milan, Italy, ⁹Department of Theology and Religious Sciences, University of Frankfurt, Frankfurt, Germany, ¹⁰Institute of Complementary and Integrative Medicine, University Hospital and University of Zurich, Zürich, Switzerland
Background/Purpose: Ayurveda is used to treat knee osteoarthritis (OA) despite limited evidence. We aimed to evaluate the effectiveness of complex multimodality Ayurvedic treatment in comparison…
Abstract Number: 717 • 2016 ACR/ARHP Annual Meeting
NSAID Use and Functional Impairment in Ankylosing Spondylitis
Mark Hwang¹, Seth Eisen¹, MinJae Lee², Michael Ward³, Lianne S. Gensler⁴, Prabha Ranganathan⁵, Johnathan Jia⁶, Amirali Tahanan², Matthew A. Brown⁷, Mohammad H. Rahbar², Michael Weisman⁸ and John D. Reveille⁹, ¹Internal Medicine-Rheumatology, Washington University in Saint Louis, School of Medicine, Saint Louis, MO, ²Biostatistics/Epidemiology/Research Design (BERD) Core | Center for Clinical and Translational Sciences, University of Texas-McGovern Medical School, Houston, TX, ³NIH/NIAMS, Bethesda, MD, ⁴Medicine/Rheumatology, UCSF, San Francisco, CA, ⁵Washington University in Saint Louis, School of Medicine, Saint Louis, MO, ⁶University of Texas-McGovern Medical School, Houston, TX, ⁷The University of Queensland Diamantina Institute, Brisbane, Australia, ⁸Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, ⁹Rheumatology, University of Texas-McGovern Medical School, Houston, TX
Background/Purpose: Ankylosing spondylitis (AS) is a chronic inflammatory disease with significant burden to patients and society. NSAIDs are the first line pharmacologic therapy in…
Abstract Number: 848 • 2016 ACR/ARHP Annual Meeting
Efficacy of Prucalopride in the Treatment of Systemic Sclerosis-Related Intestinal Involvement: Results from an Open Label Cross-over Study
Barbara Vigone¹, Monica Caronni¹, Adriana Severino¹, Chiara Bellocchi², Anna Rita Baldassarri³, Gaia Montanelli⁴, Alessandro Santaniello¹ and Lorenzo Beretta¹, ¹Scleroderma Unit, Referral Center for Systemic Autoimmune Diseases, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico di Milano, Milan, Italy, ²Scleroderma Unit, Referral Center for Systemic Autoimmune Diseases,, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico di Milano, Milan, Italy, ³Gastroenterology and Endoscopy Unit, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico di Milano, Milan, Italy, ⁴Scleroderma Unit, Referral Center for Systemic Autoimmune Diseases, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico di Milano, Milano, Italy
Background/Purpose: The gastrointestinal tract (GIT) is frequently affected in SSc patients as a consequence of a reduction in enteric propulsive forces. Due to intestinal involvement,…
Abstract Number: 867 • 2016 ACR/ARHP Annual Meeting
Termination of Tocilizumab-Treatment in Giant Cell Arteritis: Follow-up of Patients after the RCT (ClinicalTrials.gov registration number: NCT01450137)
Sabine Adler¹, Stephan Reichenbach², Stefan Kuchen³, Felix Wermelinger⁴, Diana Dan⁴, Michael Seitz⁴ and Peter M. Villiger⁴, ¹Rheumatology, Immunology, Allergology, University Hospital Bern, Bern, Switzerland, ²Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland, ³Rheumatology, Immunology, and Allergology, University of Bern, Bern, MD, Switzerland, ⁴Department of Rheumatology, Immunology and Allergology, University Hospital Bern, Bern, Switzerland
Background/Purpose:
Abstract Number: 969 • 2015 ACR/ARHP Annual Meeting
Namilumab, an Anti-Granulocyte Macrophage-Colony Stimulating Factor (GM-CSF) Monoclonal Antibody: Results of the First Study in Patients with Mild-to-Moderate Rheumatoid Arthritis (RA)
T. W. J. Huizinga¹, Anastas Batalov², Rumen Stoilov³, Eric Lloyd⁴, Thomas Wagner⁵, Didier Saurigny⁶, Bernard Souberbielle⁶ and Ehsanollah Esfandiari⁶, ¹Rheumatology, Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²UMHAT Kaspela, Plovdiv, Bulgaria, ³University Hospital (MHAT) St Ivan Rilski, Sofia, Bulgaria, ⁴Takeda Pharmaceuticals, Deerfield, IL, ⁵Takeda Pharmaceuticals, Zurich, Switzerland, ⁶Takeda Pharmaceuticals, London, United Kingdom
Background/Purpose: GM-CSF mediates a range of immunological processes, such as stimulating the production of inflammatory mediators and differentiation of proinflammatory T-helper 17 cells, and may…
Abstract Number: 1045 • 2015 ACR/ARHP Annual Meeting
Baricitinib, Methotrexate, or Baricitinib Plus Methotrexate in Patients with Early Rheumatoid Arthritis Who Had Received Limited or No Treatment with Disease-Modifying Anti-Rheumatic Drugs (DMARDs): Phase 3 Trial Results
Roy Fleischmann¹, Tsutomu Takeuchi², Douglas E. Schlichting³, William L. Macias³, Terence Rooney³, Sirel Gurbuz³, Ivaylo Stoykov³, Scott D. Beattie³, Wen-Ling Kuo³ and M Schiff⁴, ¹Rheumatology, Metroplex Clinical Research Center, Dallas, TX, ²Keio University School of Medicine, Tokyo, Japan, ³Eli Lilly and Company, Indianapolis, IN, ⁴School of Medicine, University of Colorado, Denver, CO
Background/Purpose: In 2 completed phase 3 studies, baricitinib (bari) improved disease activity with a satisfactory safety profile in patients (pts) with moderately-to-severely active RA who…
Abstract Number: 1254 • 2015 ACR/ARHP Annual Meeting
Deciphering the Immunome of Clinically Effective Immune Tolerization in Rheumatoid Arthritis
Jing Yao Leong^1,2, Raymond Ong Jr.³, Juntao Li⁴, Theodorus van den Broek⁵, Roberto Spreafico⁴, Maura Rossetti¹ and Salvatore Albani^1,2, ¹SingHealth Translational Immunology and Inflammation Centre, Singapore Health Services Pte Ltd, Singapore, Singapore, ²Duke-National University of Singapore Graduate Medical School, Singapore, Singapore, ³Singhealth Translational Immunology and Inflammation Centre (STIIC), Singapore Health Services Pte Ltd, Singapore, Singapore, ⁴SingHealth Translational Immunology and Inflammation Centre (STIIC), Singapore Health Services Pte Ltd, Singapore, Singapore, ⁵Translational Research Unit, Sanford-Burnham Medical Research Institute, La Jolla, CA
Background/Purpose: We have previously described (Nature Medicine, PNAS, A&R, Nature Rheum, Lancet) how oral treatment with the pro-inflammatory, heat shock protein-derived dnaJP1 peptide induces detectable…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.